الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 106 |  |  |
| | | from | 106 | | |
Abstract
Hepatitis C virus (HCV) infection is common and can accelerate chronic kidney disease (CKD) progression. HCV therapy in the setting of renal dysfunction has always been a challenging topic. Direct-acting antiviral (DAA) therapies against hepatitis C have consistently shown rates of sustained viral remission. However, the effect on kidney function is unknown. chronic HCV infection exacerbates renal deterioration, and increasing morbidity and mortality in patients undergoing dialysis. Interferon-based therapies have demonstrated frequent and severe side-effects. It was demonstrated that; the development of DAAs showing promising effects, even in patients with CKD. The aim of the current study was to assess the outcome of chronic HCV infected patients with CKD on hemodialysis after treatment with DAAS (Ombitasvir, Paritaprevir, and Ritonavir) with or without ribavirin. This was a prospective non randomized clinical trial that was carried out on 3 groups. group 1 (100 patients): chronic HCV infected compensated patients with CKD on chronic hemodialysis (Stage5) received treatment with DAAS (Ombitasvir, Paritaprevir, and Ritonavir) with or without ribavirin. group 2 (50 patients): chronic HCV infected compensated patients with normal renal functions received treatment with DAAS (Ombitasvir, Paritaprevir, and Ritonavir) with or without ribavirin. group 3 (50 controlled) : chronic HCV infected compensated patients with CKD on chronic hemodialysis (Stage5) who didn’t receive antiviral treatment.